Overview

Outpatient Administration of Teclistamab for Multiple Myeloma

Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This is a phase II study to evaluate the Outpatient Administration of Teclistamab in Multiple Myeloma Patients
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborator:
Janssen Research & Development, LLC